A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
This study is testing a medication called elacestrant mixed with other targeted cancer drugs to see how well they work together against advanced breast cancer. Researchers want to find the safest and most effective combination treatments to help patients live better lives.
Adults aged 18 and older with a specific type of advanced breast cancer known as ER-positive and HER2-negative may be eligible to join. Participants must meet certain health and menopausal status requirements and cannot have active cancer that has spread to the brain.
Participants will receive elacestrant paired with one of several other cancer-fighting medications to test safety and effectiveness. Doctors will closely monitor your health and how your body responds to the treatment throughout the study.
The study has locations in several U.S. states including Alabama, Arizona, and Arkansas. This study is currently active and not recruiting new participants.
- 1Tests elacestrant combined with other cancer medications
- 2Focuses on advanced ER-positive and HER2-negative breast cancer
- 3Aims to find safer and more effective treatment options
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.